DBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report report published on Tuesday morning. The firm issued a hold rating on the stock.

A number of other analysts have also commented on DBVT. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price target on shares of DBV Technologies in a research note on Tuesday, September 24th. HC Wainwright raised their price target on DBV Technologies from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th.

DBV Technologies Stock Up 3.5 %

Shares of DBVT stock opened at $0.82 on Tuesday. The stock has a fifty day moving average of $0.77 and a 200 day moving average of $0.94. DBV Technologies has a 52 week low of $0.50 and a 52 week high of $2.17. The firm has a market capitalization of $79.12 million, a price-to-earnings ratio of -0.98 and a beta of 0.67.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The business had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.42 million. During the same period in the previous year, the business earned ($0.26) EPS. Equities research analysts anticipate that DBV Technologies will post -1.43 earnings per share for the current year.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. raised its position in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the quarter. DBV Technologies comprises approximately 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th biggest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.